ישראל - עברית - Ministry of Health

novartis israel ltd - omalizumab - אבקה וממס להכנת תמיסה להזרקה - omalizumab 150 mg/dose - omalizumab - omalizumab - xolair is indicated for adults and adolescents (12 years of age and above) with moderate to severe persistent asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids. xolair has been shown to decrease the incidence of asthma exacerbations in these patients. safety and efficacy have not been established in other allergic conditions.

ישראל - עברית - Ministry of Health

novartis israel ltd - crizanlizumab - תרכיז להכנת תמיסה לאינפוזיה - crizanlizumab 10 mg/ml - crizanlizumab

ישראל - עברית - Ministry of Health

novartis israel ltd - octreotide - אבקה וממס להכנת תרחיף להזרקה - octreotide 30 mg - octreotide - octreotide - treatment of acromegaly in: patients already adequately controlled on standard doses of sandostatin s.c. patients in whom surgery or radiotherapy are inappropriate or ineffective, or who are in the latency period before radiotherapy becomes fully effective.endocrine gastro-entero- pancreatic (gep) tumors, carcinoid tumors.

ישראל - עברית - Ministry of Health

novartis israel ltd - octreotide - אבקה וממס להכנת תרחיף להזרקה - octreotide 20 mg - octreotide - octreotide - treatment of acromegaly in: patients already adequately controlled on standard doses of sandostatin s.c. patients in whom surgery or radiotherapy are inappropriate or ineffective, or who are in the latency period before radiotherapy becomes fully effective. endocrine gastro-entero- pancreatic (gep) tumors, carcinoid tumors.

ישראל - עברית - Ministry of Health

novartis israel ltd - octreotide - אבקה וממס להכנת תרחיף להזרקה - octreotide 10 mg - octreotide - octreotide - treatment of acromegaly in: patients already adequately controlled on standard doses of sandostatin s.c. patients in whom surgery or radiotherapy are inappropriate or ineffective, or who are in the latency period before radiotherapy becomes fully effective. endocrine gastro-entero- pancreatic (gep) tumors, carcinoid tumors.

ישראל - עברית - Ministry of Health

novartis israel ltd - deferoxamine mesylate - אבקה להמסה להזרקה\אינפוזיה - deferoxamine mesylate 0.5 g/vial - deferoxamine - deferoxamine - treatment of chronic iron overload e.g.: transfusional haemosiderosis especially in thalassaemia major sideroblastic anaemia autoimmune haemolytic anaemia and other chronic anaemias idiopathic (primary) haemochromatosis in patients in whom concomitant disorders ( e.g. severe anaemia cardiac disease hypoproteinaemia) preclude phlebotomy iron overload associated with porphyria cutanea tarda. treatment of acute iron poisoning. treatment of chronic aluminium overload in patients with terminal renal failure (under maintenance dialysis) with: aluminium-related bone disease and/or dialysis encephalopathy and/or aluminium-related anaemia. diagnosis of iron overload.

ישראל - עברית - Ministry of Health

novartis israel ltd - glycopyrronium as bromide - אבקה לשאיפה בקפסולות קשיחות - glycopyrronium as bromide 50 mcg - glycopyrronium

ישראל - עברית - Ministry of Health

novartis israel ltd - onasemnogene abeparvovec - תרחיף - onasemnogene abeparvovec 2 x 10^13 vg / 1 ml - onasemnogene abeparvovec

ישראל - עברית - Ministry of Health

novartis israel ltd - brolucizumab - תמיסה להזרקה - brolucizumab 120 mg / 1 ml - brolucizumab

ישראל - עברית - Ministry of Health

novartis israel ltd - hydrochlorothiazide; valsartan - טבליות מצופות פילם - valsartan 80 mg; hydrochlorothiazide 12.5 mg - valsartan and diuretics - valsartan and diuretics - co-diovan is indicated for the treatment of hypertension for patients in whom combination therapy is appropriate.